Cited by 317Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesEstrogen and related hormone effects

The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Burstein, Harold J.·2020·New England Journal of Medicine

Open this paper in CoChat — free account

Abstract

ER-positive, HER2-negative breast cancer, which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy is the cornerstone of systemic therapy, and its efficacy depends on such factors as grade, Ki-67 labeling, and progesterone receptor expression.

Integrity signals

Registry

Crossref · 10.1056/nejmra1307118

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J. B., Kim, W., Cronin, M. T., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,597
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,054

Show all 106 references

Research works printed but not linked: 2

Kalinsky K Barlow WE Meric-Bernstam F et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes hormone receptor positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) <25: SWOGS1007 (RxPONDER). Presented at the virtual San Antonio Breast Cancer Symposium December 8–11 2020. abstract.
Mayer EL Gnant M DeMichele A et al. PALLAS: a randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. Presented at the ESMO Virtual Congress September 20 2020. abstract. · DOI

Sorted by citations

Items 101–200 of 317

FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1 -Mutant Breast Cancer
Wu, Y., Li, Z., Wedn, A. M., Casey, A. N., Brown, D. D., Rao, S. V., Omarjee, S., Hooda, J., Carroll, J. S., Gertz, J., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0516 · Cited by 12
Fasting boosts breast cancer therapy efficacy via glucocorticoid activation
Padrão, N., Severson, T., Gregoricchio, S., Guijarro, A., Lutz, C., Taranto, D., Hutten, S. J., Ligorio, F., Persia, A., Roest, M., et al. (2025) · Nature · doi:10.1038/s41586-025-09869-0 · Cited by 14
Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention
Lei, H., Fu, J., Gu, W., Qiao, H., Guo, H., Chen, Z., Wang, S. M., & Chen, T. (2026) · MedComm · doi:10.1002/mco2.70560 · Cited by 15
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer
Martínez-Pérez, C., Turnbull, A., Kay, C., & Dixon, J. M. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2162043 · Cited by 11
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer
López-Velazco, J. I., Manzano, S., Otaño, M., Elorriaga, K., Bultó, N., Herrero, J. J., Lahuerta, A., Segur, V., Álvarez, I., Caffarel, M. M., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-023-01756-8 · Cited by 11
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
Brett, J. O., & Mayer, E. L. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01082-3 · Cited by 13
Unmet challenges in systemic therapy for early stage breast cancer
Burstein, H. J. (2021) · The Breast · doi:10.1016/j.breast.2021.12.009 · Cited by 11
Self-citation
The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients
Ma, Q., Liu, Y., She, T., & Liu, X. (2024) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s451617 · Cited by 10
Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial
Vidal, M. J., Falato, C., Pascual, T., Sánchez-Bayona, R., Muñoz-Mateu, M., Cebrecos, I., González, X., Cortadellas, T., Vila, M. M., Luna, M. A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2460 · Cited by 10
Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysis
Fang, D., Li, Y., Li, Y., Chen, Y., Huang, Q., Luo, Z., Chen, J., Li, Y., Wu, Z., Huang, Y., et al. (2022) · Gland Surgery · doi:10.21037/gs-22-234 · Cited by 10
Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?
Benvenuti, C., Laot, L., Grinda, T., Lambertini, M., Pistilli, B., & Grynberg, M. (2024) · ESMO Open · doi:10.1016/j.esmoop.2023.102228 · Cited by 10
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
Puglisi, F., Gerratana, L., Lambertini, M., Ceppi, M., Boni, L., Montemurro, F., Russo, S., Bighin, C., Laurentiis, M. D., Giuliano, M., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00286-w · Cited by 10
Fulfilling the Role of a Parent While Undergoing Treatment for Cancer
Kim, K. W., Lopresti, M. L., Graff, S. L., Witherby, S. M., Dizon, D. S., & Fenton, M. A. (2024) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001102 · Cited by 10
Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer
O'Keefe, K., Desai, N. V., & Tan, A. R. (2024) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s271441 · Cited by 9
Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion
Kastora, S. L., Pantiora, E. V., Hong, Y. H., Veeramani, M., Azim, H. A., Chakrabarti, R., Geisler, J., Knoop, A. S., Lambertini, M., Linderholm, B. K., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102880 · Cited by 9
Exogenous melatonin alleviates premature ovarian failure by regulating granulosa cell autophagy
Zhou, G.-H., He, Y., Wang, H.-L., Lv, Y.-B., Cong, Y., Sun, Z.-L., Jiang, X., & Yu, W. (2025) · npj Regenerative Medicine · doi:10.1038/s41536-025-00422-1 · Cited by 9
TRIM24 as a therapeutic target in endocrine treatment–resistant breast cancer
Padrão, N., Gregoricchio, S., Eickhoff, N., Dong, J., Luzietti, L., Bossi, D., Severson, T., Siefert, J. C., Calcinotto, A., Buluwela, L., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2507571122 · Cited by 9
Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?
Méry, B., Poulard, C., Romancer, M. L., & Trédan, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413512 · Cited by 9
Development of PROTACs targeting estrogen receptor: an emerging technique for combating endocrine resistance
Peng, R., Liu, X., Chen, C., Guo, R., & Min, J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00961d · Cited by 8
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences
Scafetta, R., Zagami, P., Re, M. D., Criscitiello, C., Marra, A., & Curigliano, G. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07595-1 · Cited by 8
Long-term Outcomes for Neoadjuvant Versus Adjuvant Chemotherapy in ER+/HER2− Locally Advanced Breast Cancer
Wang, J., Yang, B., Bian, L., Zhang, H., Peng, C. Y., Zou, Y., & Tang, H. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17297-7 · Cited by 8
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
Zhu, X.-Z., Zhang, H.-Y.-L., Zhou, Y.-F., Chen, Y.-Y., Fu, T., Jin, M.-L., Zhao, Y.-X., Xie, Y.-F., Zeng, X., Jin, X., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-5002 · Cited by 8
Hepatic resection for breast cancer related liver metastases: A single institution experience
Reynolds, I. S., Cromwell, P. M., Walshe, J. M., Crown, J. P., Maguire, D., Geoghegan, J., Swan, N., & Hoti, E. (2022) · Scandinavian Journal of Surgery · doi:10.1177/14574969221088685 · Cited by 9
Risk of estrogen receptor–specific breast cancer by family history of estrogen receptor subtypes and other cancers
Wang, Q.-L., Zhang, Y., Zeng, E., Graßmann, F., He, W., & Czene, K. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad104 · Cited by 8
Deep learning-enabled breast cancer endocrine response determination from H&E staining based on ESR1 signaling activity
Ng, C. W., & Wong, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-48830-x · Cited by 8
DREAM On, DREAM Off: A Review of the Estrogen Paradox in Luminal A Breast Cancers
Hugh, J. C., Haddon, L. S. J., & Githaka, J. M. (2024) · Biomedicines · doi:10.3390/biomedicines12061300 · Cited by 9
Ultrasound-Responsive Hydrogel Incorporated with TGF-β Mimetic Peptides for Endometrium Recovery to Restore Fertility
Qin, J., Sun, M., Cheng, J., Jiang, H., Lv, M., Jing, J., Chen, R., Fan, Z., & Du, J. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c07290 · Cited by 8
A comprehensive luminal breast cancer patient‐derived xenografts ( PDX ) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4 /6 inhibitors
Segatto, I., Mattevi, M. C., Vinciguerra, G. L. R., Crestan, N., Musco, L., Favero, A., Dall’Acqua, A., Giustino, G. D., Mungo, G., D’Andrea, S., et al. (2024) · The Journal of Pathology · doi:10.1002/path.6358 · Cited by 8
Importance of Patient Education for At-home Yoga Practice in Women With Hormonal Therapy-induced Pain During Adjuvant Breast Cancer Treatment: A Feasibility Study
Faravel, K., Huteau, M.-È., Jarlier, M., de Forges, H., Meignant, L., Sénesse, P., Norton, J. L., Jacot, W., & Stœbner-Delbarre, A. (2021) · Integrative Cancer Therapies · doi:10.1177/15347354211063791 · Cited by 10
Differential Gene Analysis of Trastuzumab in Breast Cancer Based on Network Pharmacology and Medical Images
Lu, Y., Bi, J., Li, F., Wang, G., Zhu, J., Jin, J., & Liu, Y. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.942049 · Cited by 8
Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review
Mata, D. G. D. M. M., Carmona, C. A., Eisen, A. F., & Trudeau, M. (2022) · Current Oncology · doi:10.3390/curroncol29070394 · Cited by 8
Migraine and Risk of Breast Cancer: A Systematic Review and Meta-analysis
Peng, C., Wu, K., Chen, X., Lang, H., Li, C., He, L., & Chen, N. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.12.011 · Cited by 8
Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Patients Treated With Mastectomy: Indications for Treatment and Oncological Outcomes
Tinterri, C., Darwish, S. S., Barbieri, E., Sagona, A., Vinci, V., & Gentile, D. (2024) · European Journal of Breast Health · doi:10.4274/ejbh.galenos.2024.2024-6-3 · Cited by 7
Reversal of postoperative breast cancer metastasis by the use of embedded hydrogel
Yu, Z. (2024) · American Journal of Translational Research · doi:10.62347/vzaw2270 · Cited by 7
Discovery of Thiochroman Derivatives as Potent, Oral Selective Estrogen Receptor Degraders and Antagonists for the Treatment of Endocrine-Resistant Breast Cancer
Zhang, D., Lu, Z., He, Y., Leng, X.-Y., Meng, X., Lei, X., Kong, D., Sun, L., Hu, W., & Yang, Y. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02453 · Cited by 7
PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence
Zhan, H., Antony, V. M., Tang, H., Theriot, J., Liang, Y., Hui, P., Krishnamurti, U., & DiGiovanna, M. P. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07660-3 · Cited by 8
Identification of gene signatures associated with lactation for predicting prognosis and treatment response in breast cancer patients through machine learning
Zhao, J., Li, L., Wang, Y., Huo, J., Wang, J., Xue, H., & Cai, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-98255-x · Cited by 7
MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment
Nakashoji, A., Bhattacharya, A., Ozawa, H., Haratake, N., Shigeta, K., Fushimi, A., Yamashita, N., Matsui, A., Kure, S., Kameyama, T., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00751-w · Cited by 7
18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature
Bodapati, S., Abraham, P., Chen, A., Guilbault, D., McDonald, M. A., Matro, J. M., Shatsky, R. A., & Obrzut, S. L. (2022) · Tomography · doi:10.3390/tomography8020086 · Cited by 7
Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer
da Silva, F. C., Brandão, D. C., Ferreira, E. A., Siqueira, R. P., Ferreira, H. S. V., Filho, A. A. D. S., & Araújo, T. G. (2023) · Pharmaceuticals · doi:10.3390/ph16101466 · Cited by 7
Multi-omics analysis of the effects of pla2g4a on the prognosis of various cancers and its experimental validation in breast cancer cell lines
Qian, Y., Yuan, Q., Yu, H., Ye, R., Niu, M., & Liu, F. (2025) · Discover Oncology · doi:10.1007/s12672-025-03118-6 · Cited by 6
Tumor-associated neutrophil precursors impair homologous DNA repair and promote sensitivity to PARP inhibition
Mukherjee, S., Garda, C., Boffa, L., Elia, A. R., Massara, M., Balia, M. T., Brina, D., Mosole, S., Campagnari, A., Cassanmagnago, G. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61422-9 · Cited by 6
Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer
Ravani, L. V., Bagheri, Z., Brufsky, A., Michelon, I. F., O'Regan, R. M., Lustberg, M. B., Han, H. S., Wang, M., & Wander, S. A. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02095-6 · Cited by 6
Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis
Chen, R., Yu, Y., Zhang, J., Song, C., & Wang, C. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2350105 · Cited by 6
Estrogen Receptor–targeted PET Imaging for Breast Cancer
Zhou, W., Franc, B. L., DeMartini, W. B., & Rosen, E. L. (2024) · Radiology · doi:10.1148/radiol.240315 · Cited by 6
Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer
Ruckhäberle, E., Schmidt, M., Welt, A., Harbeck, N., Wöckel, A., Gluz, O., Park‐Simon, T., Untch, M., & Lux, M. P. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2344-5269 · Cited by 6
Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer
Xu, Y., Qi, Y., Lu, Z., Tan, Y., Chen, D., & Luo, H. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2405060 · Cited by 6
Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer
Johnston, S. R. D. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.08.011 · Cited by 6
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research
Conforti, F., Pala, L., Pas, T. M. D., Zattarin, E., Catania, C., Cocorocchio, E., Rossi, G., Laszlo, D., Colleoni, M. A., Zambelli, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1836 · Cited by 6
Establishment of a tumor immune microenvironment-based molecular classification system of breast cancer for immunotherapy
Zheng, X., Li, L., Yu, C., Yang, J., Zhao, Y., Su, C., Yu, J., & Xu, M. (2021) · Aging · doi:10.18632/aging.203682 · Cited by 6
Treatment of HR+/HER2− breast cancer in urban mainland China: results from the CancerMPact Survey 2019
Murali, B., Durbin, L. L., Vijaykumar, S., Yang, L. C., Li, S., Zhao, L. H., Hawthorne, S., Kanas, G., Davis, C., & Clark, O. A. C. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06709-x · Cited by 6
Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis
Zhang, Z., Zhao, X., & Chen, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1438288 · Cited by 5
The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions
Laface, C., Giuliani, F., Melaccio, A., Pappagallo, M. N., Santoro, A. N., Perrone, M., Santis, P. D., Guarini, C., Carrozzo, D., & Fedele, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186012 · Cited by 5
Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database
Kumar, P. A., Wang, D., Huang, D., & Sivapiragasam, A. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00390 · Cited by 5
PTX-RPPR, a conjugate of paclitaxel and NRP-1 peptide inhibitor to prevent tumor growth and metastasis
Li, Y., Feng, Q., Gao, Q., Wang, Y., Zhao, S., Zhang, X., & Zhao, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117264 · Cited by 5
Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors
Jeong, H., Ryu, J., Jeong, J. H., Han, S., Hyung, J., Ahn, J., Jung, K. H., Kim, S.-B., Jeong, B.-K., Lee, H. J., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07058-1 · Cited by 6
Ovarian escape in premenopausal breast cancer: Challenges and strategies for optimizing hormone suppression
Luo, L., Zhang, Y.-L., Zhang, L., Yang, S., Zhou, T., Luo, K., & Liu, S. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102970 · Cited by 5
Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer
Thang, N. X., Yoo, S., La, H., Lee, H., Park, C., Park, K. S., & Hong, K. (2022) · Biomedicines · doi:10.3390/biomedicines10040748 · Cited by 5
Sex differences in the cardiovascular effects of GnRH analogues
Lim, M. W. S., Lucas-Herald, A. K., Mason, A., Delles, C., & Connelly, P. J. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0309 · Cited by 5
RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid
Yu, Y., Xu, Z., Zhou, H., Xu, R., Xu, J., Liu, W., Wu, Y., Qiu, Y., Zhang, G., Huang, X. F., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03299-0 · Cited by 5
Design and synthesis of phosphoryl-substituted steroidal pyridazines (Pho-STPYRs) as potent estrogen receptor alpha inhibitors: targeted treatment of hormone-dependent breast cancer cells
Volkova, Y. A., Scherbakov, A. M., Dzichenka, Y. U., Komkov, A., Bogdanov, F. B., Salnikova, D. I., Dmitrenok, A. S., Sachanka, A. B., Sorokin, D. V., & Zavarzin, I. V. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00153b · Cited by 5
Advances in combination therapy for the treatment of estrogen receptor positive breast cancer
Liu, L., Zhao, Z., Zou, F., Lu, Y., & Lu, Y. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111451 · Cited by 4
Bibliometric analysis and visualization of endocrine therapy for breast cancer research in the last two decade
Wang, D., Yang, Y., Yang, L., & Yang, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1287101 · Cited by 4
Inhibition of ERK signaling for treatment of ERRα positive TNBC
Musheyev, D., Miller, E., Birnbaum, N., Miller, E., Erblich, S., Schuck, A. G., & Alayev, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283047 · Cited by 4
Concordance of RT-qPCR with immunohistochemistry and its beneficial role in breast cancer subtyping
Li, Y., Chen, T., Du, F., Wang, H., & Ma, L. (2023) · Medicine · doi:10.1097/md.0000000000035272 · Cited by 4
A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER− cells via endoplasmic reticulum stress-induced apoptosis
Yang, T.-L., Li, W., Zhou, J., Xu, M. J., Huang, Z., Ming, J., & Huang, T. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06539-3 · Cited by 4
Elacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review
Qureshi, Z. A., Jamil, A. R., Altaf, F., Siddique, R., Adilovic, E., Fatima, E., & Shah, S. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002293 · Cited by 6
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
Kahraman, S., Erul, E., Gümüşay, Ö., Güven, D. C., Aksoy, S., Başaran, G., Seyyar, M., Şahin, E., Cabuk, D., Bayram, E., et al. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.03.003 · Cited by 5
Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years
Dredze, L. M., Friger, M. D., Ariad, S., Koretz, M. J., Delgado, B., Shaco‐Levy, R., Tokar, M., Bayme, M., Agassi, R., Rosenthal, M., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06598-0 · Cited by 4
Systems biology based miRNA–mRNA expression pattern analysis of Emodin in breast cancer cell lines
Sakalli-Tecim, E., Dedeoğlu, B. G., & Güray, T. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154780 · Cited by 4
Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K
Hayashi, K., Hoshii, T., Ning, M., Matsumoto, M., Izumi, S., Fukuyo, M., Rahmutulla, B., Tanabe, M., & Kaneda, A. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02101-x · Cited by 3
A systematic review of progress toward unlocking the power of epigenetics in breast cancer: latest updates and perspectives
Alotaibi, G. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1628165 · Cited by 3
Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm: a SEER population-based study
Zheng, Y.-Z., Zhan, Z. Z., Wu, T., Ying, J.-Q., & Zheng, A.-N. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf422 · Cited by 3
Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer
Hsu, E., Arezo, S. M., & Graff, S. L. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01258-5 · Cited by 5
Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response
López-Velazco, J. I., Manzano, S., Elorriaga, K., Otaño, M., Lahuerta, A., Álvarez, L., Etxabe, I., Huarte, M., Buch, E., Giménez, J., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102407 · Cited by 3
DREAM, a possible answer to the estrogen paradox of the Women's Health Initiative Trial
Hugh, J. C., Haddon, L. S. J., Githaka, J. M., Bigras, G., Hu, X., Madden, B., Hanson, J., Gabos, Z., Giannakopoulos, N. V., Huang, F., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08666 · Cited by 3
Palbociclib-associated nephrotoxicity in a patient with breast cancer
Tang, S.-Y., Peng, C., Lin, T., Chang, F., & Hung, S. (2024) · Journal of Onco-Nephrology · doi:10.1177/23993693241232733 · Cited by 3
Therapeutic significance of long noncoding RNAs in estrogen receptor‐positive breast cancer
Alzahrani, A. A., Saleh, R. O., latypova, A., Bokov, D. O., Kareem, A. H., Talib, H. A., Hameed, N. M., Pramanik, A., Alawadi, A. H., & Alsalamy, A. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3993 · Cited by 3
Brain metastasis risk prediction model in females with hormone receptor-positive breast cancer
Díaz, B. C., Valdés‐Ferrer, S. I., Chávez‐MacGregor, M., Salmerón‐Moreno, K., Villarreal-Garza, C. M., & Reynoso‐Noverón, N. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110379 · Cited by 3
Selective Estrogen Receptor Degraders (SERDs)
Taylor, M., Kahn, A. M., & Foldi, J. (2024) · Current Breast Cancer Reports · doi:10.1007/s12609-024-00563-0 · Cited by 3
A Research Protocol for a Phase II Single-Arm Clinical Trial Assessing the Feasibility and Efficacy of Neoadjuvant Anastrozole in Patients With Luminal Breast Cancer and Low Proliferative Index: The ANNE Trial
Paiva, C. E., Silva, A. T. F., Oliveira, I. D. S., Guimarães, V. S., Lacerda, D. C., Teixeira, G. R., Watanabe, A. H. U., Onari, N., Paiva, B. S. R., Junior, I. D. O., et al. (2024) · Cancer Control · doi:10.1177/10732748241272463 · Cited by 3
Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccine
Knöbl, V., Maier, L., Grasl, S., Kratzer, C., Winkler, F., Eder, V., Hayden, H., Cortez, M. A. S., Sachet, M., Oehler, R., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05659-w · Cited by 3
18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival
Xie, Y., Chen, Y., Liu, C., Zhao, Y., Gong, C., Lin, S., Song, S., Wang, B., & Yang, Z. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07459-w · Cited by 4
Improving Outcomes for High-Risk Hormone Receptor–Positive Breast Cancer With CDK Inhibition
Hicks, D. G., & O'Regan, R. M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02850 · Cited by 3
Impact of Different Modules of 21-Gene Assay in Early Breast Cancer Patients
Chen, M., Liu, D., Chen, W., Chen, W., Shen, K., Wu, J., & Zhu, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.759338 · Cited by 3
Role of Estrogen Receptor-Positive/Negative Ratios in Regulating Breast Cancer
Li, Y., Zhang, H., Jiang, T., & Li, P. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/7833389 · Cited by 3
Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature
Chamorro, Y., Sandoval-Leon, A. C., Vogel, C. L., Nguyen, M. T., & Wang, G. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03679-y · Cited by 3
Exploring the Potential of Adjuvant CDK4/6 Inhibitors in Hormone Receptor-Positive Early Breast Cancer: A Consistent Approach for All
Li, J. (2025) · Cancers · doi:10.3390/cancers17040561 · Cited by 2
Combined Radiation and Endocrine Therapies Elicit Benefit in ER+ Breast Cancer
Johnson, A. L., Tau, S. S., Sloop, A. M., Dai, T., Roberts, A. M., Muskus, P. C., Warren, A., Kleist, S. A., Hampsch, R. A., Jorns, J. M., et al. (2025) · Cancers · doi:10.3390/cancers17121921 · Cited by 2
Endocrine therapy resistance of breast cancer: Important role of G protein-coupled estrogen receptor (GPER) and new therapeutic strategies
Yu, T., He, C., Zhang, H., Zhu, Y., Wang, A., Zeng, X., Huang, Y., Zhong, J., Wu, X., Shu, Y., et al. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101716 · Cited by 3
Comprehensive safety assessment of ribociclib: A real‐world analysis using the FDA Adverse Event Reporting System (FAERS) database
Luo, L., Wang, Y., Fu, Y., Chen, X., Liu, S., & Zhao, B. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70265 · Cited by 2
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34
Kacerovsky-Strobl, S., Deutschmann, C., Hlauschek, D., Bagó-Horváth, Z., Singer, C. F., Bartsch, R., Greil, R., Sotlar, K., Rinnerthaler, G., Petru, E., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.104633 · Cited by 2
Molecular and cellular composition changes after neoadjuvant letrozole and palbociclib in early luminal breast cancer
Cottu, P. H., Kieffer, Y., Lemonnier, J., D’Hondt, V., Duhoux, F. P., Callens, C., Gentien, D., Réyès, C., Boulai, A., Desmoulins, I., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102544 · Cited by 2
Past, present, and future perspectives in estrogen-receptor-low breast cancer
Courtès, D. M.-G., Florea, D. C., & Anchisi, S. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105326 · Cited by 2
Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis
Gandini, S., Guerrieri‐Gonzaga, A., Serrano, D., Rizzo, R., Lazzeroni, M., Puntoni, M., Webber, T. B., Aurilio, G., Johansson, H. A., Carbone, A., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00841 · Cited by 2
Statin use in patients with hormone receptor‐positive metastatic breast cancer treated with everolimus and exemestane
Lee, K., Noh, E., Moon, S. J., Joo, Y. Y., Kang, E. J., Seo, J. H., & Park, I. H. (2022) · Cancer Medicine · doi:10.1002/cam4.5369 · Cited by 2
The Impact of Breast Cancer Type, Staging, and Treatment on Vascular Complications of Immediate Free-Flap Breast Reconstruction
Talwar, A. A., Mazzaferro, D. M., Morris, M. P., Davis, H. D., Hitchner, M. K., Shulkin, J. M., Christopher, A. N., Broach, R. B., Brooks, A. D., & Serletti, J. M. (2023) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000003411 · Cited by 2
Hormonal therapy
De, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13312-1.00006-4 · Cited by 2
Factors Associated With Node-Positive Disease in Estrogen Receptor-Positive Breast Cancer Patients
Gallagher, J. E., Elleson, K. M., Englander, K., Chintapally, N., Sun, W., Whiting, J., Laronga, C., & Lee, M. C. (2023) · Journal of Surgical Research · doi:10.1016/j.jss.2023.11.030 · Cited by 2
Efficacy of a physiotherapy, yoga and patient education programme for patients with breast cancer and hormone therapy-induced pain: a multicentre randomised study protocol (SKYPE 2)
Faravel, K., Jarlier, M., Meignant, L., Thomaso, M., Rio, M. D., Jacot, W., & Stoebner, A. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-075378 · Cited by 2

Authors: Burstein, H. J.
Affiliations: Brigham and Women's Hospital (US)
Corresponding author: Burstein, Harold J.
ORCID: Burstein, Harold J.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-12-24
Volume: 383
Issue: 26
Pages: 2557-2570
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra1307118
OpenAlex: W3116128628
Cited by: 316
References: 106
Citations by year: 2026: 51 · 2025: 53 · 2024: 67 · 2023: 62 · 2022: 53 · 2021: 30
FWCI: 3.70
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords: estrogen receptor-positive breast cancer, HER2-negative breast cancer, systemic therapy, antiestrogen therapy, breast cancer heterogeneity, progesterone receptor expression, tumor grade
MeSH terms: Breast Neoplasms, Female, Humans, Prognosis, Receptors, Estrogen, Chemotherapy, Adjuvant, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Neoadjuvant Therapy, Selective Estrogen Receptor Modulators, Estrogen Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks